Re-positioning of FDA-Approved Compounds in MPS III Cell Models

Cure Sanfilippo Foundation is funding search to explore re-positioning FDA-approved compounds using cell-based, high-content screening in Sanfilippo Syndrome (MPS III) cell models. 

Awardee: Diego Medina, PhD- Telethon Institute of Genetics and Medicine (TIGEM)- Italy 

Start Date: June 2018

Cure Sanfilippo Foundation

501c3 non-profit
(Tax ID: 46-4322131)

curesff@gmail.com

P.O. Box 6901
Columbia, SC 29260

N